

November 09, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the quarter and half year ended September 30, 2017

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2017.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary & Legal Head



Encl: As above

Dr. Lal PathLabs Limited records revenue growth of 6.1% in Q2FY2017-18

New Delhi, India, Nov 9, 2017 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2017

Consolidated Performance Highlights: Q2FY2017-18 vs. Q2FY2016-17
Revenue growth: 6.1% Normalised EBITDA at Rs 807 mn, PBT at Rs 778 mn
Normalised EBITDA margins healthy at 29% and
PBT margin at 28%

- Operating Revenue increased by 6.1% in Q2 to Rs. 2781 million vs Rs 2622 million in the previous year same quarter. Underlying volume growth is 6.7% during the quarter. For the six month period to September 2017 revenue grew 8.7% to Rs 5274 million with volume growing 7.6%
- Normalised EBITDA in Q2FY18 was Rs.807 million from Rs 819 million in the same quarter last year, after adjusting for RSU and other stock based compensation costs. First half normalised EBITDA grew 3.8% to Rs 1487 mn
- EBITDA Margin was strong at 29% for Q2 FY18 vs 31.3% in Q2 FY17 and for first half EBITDA margin was 28.2%
- PBT was Rs 778 mn in Q2 vs Rs 803 mn in Q2 last year while first half PBT at Rs 1438 mn grew 2.2%
- Profit after Tax in Q2FY18 at Rs. 510 million compares with Rs 529 million in Q2 last year. First half PAT at Rs 956 mn grew 3%
- The Board has recommended an interim dividend of Rs 1.50 per equity share of Rs 10 each

Financial Overview (Consolidated) in Rs mn

Particulars	FH FY 18	FH FY 17	Gr %	SQ FY 18	SQ FY 17	Gr %
Total Revenue	5,273.6	4,850.1	8.7%	2,781.0	2,621.7	6.1%
Total Expenditure	3,840.0	3,444.7		2,002.6	1,821.8	
EBITDA	1,433.6	1,405.4	2.0%	778.4	799.9	-2.7%
RSU and stock based comp. cost	53.7	26.9		28.9	19.5	
Normalised EBITDA excl RSU	1,487.3	1,432.3	3.8%	807.3	819.4	-1.5%
<i>Normalised Margins</i>	<i>28.2%</i>	<i>29.5%</i>		<i>29.0%</i>	<i>31.3%</i>	
Other income incl interest	152.0	133.8	13.6%	77.4	69.5	11.4%
PBT	1,438.4	1,407.9	2.2%	778.2	803.1	-3.1%
<i>Margins</i>	<i>27.3%</i>	<i>29.0%</i>		<i>28.0%</i>	<i>30.6%</i>	
PAT	955.5	927.7	3.0%	510.0	528.8	-3.6%
<i>Margins</i>	<i>18.1%</i>	<i>19.1%</i>		<i>18.3%</i>	<i>20.2%</i>	
EPS (Basic)	11.61	11.35	2.3%	6.19	6.47	-4.4%
EPS (Diluted)	11.60	11.27	3.0%	6.19	6.43	-3.8%

Figures have been recast as per Ind AS requirements

Dr. Lal Pathlabs Limited

12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi, 188 other clinical laboratories, 1,759 patient service centers and 5,021 pickup points as of March 31, 2017. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.